Analysts’ Opinions Are Mixed on These Healthcare Stocks: IQVIA Holdings (IQV), Qiagen (QGEN) and Ligand Pharma (LGND)
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on IQVIA Holdings (IQV – Research Report), Qiagen (QGEN – Research Report) and Ligand Pharma (LGND – Research Report).
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
IQVIA Holdings (IQV)
Stifel Nicolaus analyst Shlomo Rosenbaum maintained a Buy rating on IQVIA Holdings today and set a price target of $220.00. The company’s shares closed last Thursday at $180.96, close to its 52-week low of $176.03.
According to TipRanks.com, Rosenbaum is a 4-star analyst with an average return of
Currently, the analyst consensus on IQVIA Holdings is a Moderate Buy with an average price target of $248.82, which is a 24.5% upside from current levels. In a report issued on February 3, BMO Capital also maintained a Buy rating on the stock with a $260.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
Qiagen (QGEN)
Stifel Nicolaus analyst Daniel Arias maintained a Hold rating on Qiagen today and set a price target of $50.00. The company’s shares closed last Thursday at $51.23.
According to TipRanks.com, Arias is a 3-star analyst with an average return of
Currently, the analyst consensus on Qiagen is a Moderate Buy with an average price target of $55.48, implying an 11.2% upside from current levels. In a report issued on January 22, Deutsche Bank also downgraded the stock to Hold.
Ligand Pharma (LGND)
In a report released today, Annabel Samimy from Stifel Nicolaus maintained a Buy rating on Ligand Pharma, with a price target of $230.00. The company’s shares closed last Thursday at $191.69.
According to TipRanks.com, Samimy is a 5-star analyst with an average return of
Ligand Pharma has an analyst consensus of Strong Buy, with a price target consensus of $243.50, implying a 24.1% upside from current levels. In a report issued on January 29, Craig-Hallum also maintained a Buy rating on the stock.
